Christoph Oing

Young Oncologists Committee member

Address Dept. of Oncology Haematology and Bone Marrow Transplantation
University Medical Centre Eppendorf



What is your current activity?

After finishing med school in 2010, I started my residency at the department of Oncology, Haematology and BMT at University Medical Centre Eppendorf and I am currently working as both, a clinical fellow in my last year of clinical education, and as a post-doc in the lab of Radiobiology and Experimental Radiation Oncology.

Clinically, I am focusing on genitourinary malignancies, particularly testicular cancer and prostate cancer, as well as palliative care. In the lab, my work focuses on epigenetic mechanisms of resistance to cisplatin in germ cell tumours and to androgen-deprivation in prostate cancer. Clinical scientific projects mainly focus on challenges regarding the care of poor risk and refractory germ cell tumour patients.

As a member of the German Society of Haematology and Oncology (DGHO) and the German Testicular Cancer Study Group (GTCSG) I am actively participating in guideline development on diagnosis, treatment and follow-up of testicular cancer patients. Moreover, I recently took part in an ESMO expert consensus conference on testicular cancer.

What motivates you?

Taking good care of my patients as a perceptive and well informed physician and a personal contribution to research activities in the fight against cancer motivates me most.

Why did you choose to become a medical oncologist?

Malignant tumours are savage but biologically fascinating and the field of oncology is evolving breathtakingly fast. The close relationship between clinical care of patients and translational science convinced me during my third year at med school, already. The opportunity of being both, a thoughtful physician for each individual patient, and a scientist looking into mechanisms of tumour biology more generally is challenging but great and made me become a medical oncologist.

What does your involvement with ESMO and the Young Oncologists Committee (YOC) mean to you?

Personally, I feel honoured to be part of ESMO’s YOC and to participate in an international network of highly motivated, competent and ambitious colleagues to identify and address together the needs of young medical oncologists all over Europe. Becoming actively involved in the ESMO society may help to develop and realise personal plans and projects in the future.

Do you have some good advice you would like to share with your international colleagues?

Whatever you are up to, for clinical practice, clinical research, basic or translational science or a combination of all these aspects of oncology, networking is indispensable. Networking with young colleagues (nationally and internationally) is a great opportunity to widen your horizon and to realise personal career plans and projects more successfully.